// App-Quantinova.ai

TPS5610 : WEE WIN: Window of opportunity study of induction Wee1 inhibition in advanced high-grade serous ovarian cancer.

Researchers

Presenter

  • Shannon Neville Westin

Principal Investigators

  • Susan M. Galbraith

  • Robert Godin

  • Mark J. O'Connor

  • Mark F. Munsell

  • Katerina Savelieva

  • Alpa Manchandia Nick

  • Pamela T. Soliman

  • Anil Sood

  • Gordon B. Mills

  • Robert L. Coleman

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • AstraZeneca, Kermincham Cheshire, United Kingdom

  • Astra Zeneca Oncology, Early Clinical Development, Waltham, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • High grade serous ovarian cancer

  • Fallopian tube cancer

  • Gynaecological cancer

Biomarkers

  • Carbohydrate antigen 125

  • Plasma cell-free DNA

Drug/Treatment

  • AZD-1775

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02659241

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved